Physicians voiced their support of outcomes-based pricing for experimental and expensive biopharmaceutical drugs in an Ideas and Opinions article published online in the Annals of Internal Medicine. The authors, led by Dr. Daniel Blumenthal of Massachusetts General Hospital, note that outcomes-based pricing could increase access to treatments while keeping costs down and “would compel manufacturers and insurers to share accountability for clinical outcomes.”